vTv Therapeutics (NASDAQ:VTVT) Stock Price Passes Below Fifty Day Moving Average - What's Next?

vTv Therapeutics Inc. (NASDAQ:VTVT - Get Free Report)'s stock price passed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $36.66 and traded as low as $31.73. vTv Therapeutics shares last traded at $31.80, with a volume of 24,015 shares traded.

Analyst Ratings Changes

VTVT has been the topic of several research reports. Roth Mkm initiated coverage on vTv Therapeutics in a report on Thursday, January 22nd. They set a "buy" rating and a $58.00 price objective on the stock. BTIG Research reiterated a "buy" rating and set a $49.00 target price on shares of vTv Therapeutics in a research report on Wednesday, March 11th. Weiss Ratings reiterated a "sell (d-)" rating on shares of vTv Therapeutics in a research report on Friday, March 27th. Wall Street Zen upgraded shares of vTv Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, March 14th. Finally, Evercore initiated coverage on shares of vTv Therapeutics in a research report on Thursday, March 12th. They set an "outperform" rating and a $44.00 target price for the company. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $53.00.

vTv Therapeutics Stock Performance

The firm's 50-day simple moving average is $36.66 and its 200 day simple moving average is $33.51. The company has a market cap of $125.29 million, a P/E ratio of -9.49 and a beta of 0.26.

vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last released its quarterly earnings data on Tuesday, March 10th. The biotechnology company reported ($0.58) EPS for the quarter, beating analysts' consensus estimates of ($1.09) by $0.51. As a group, research analysts forecast that vTv Therapeutics Inc. will post -2.66 earnings per share for the current year.

Institutional Trading of vTv Therapeutics

A number of large investors have recently made changes to their positions in VTVT. Baker BROS. Advisors LP increased its position in shares of vTv Therapeutics by 52.4% in the 3rd quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company's stock valued at $3,463,000 after buying an additional 51,000 shares in the last quarter. Geode Capital Management LLC increased its position in shares of vTv Therapeutics by 84.3% in the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company's stock valued at $1,128,000 after buying an additional 12,896 shares in the last quarter. Goldman Sachs Group Inc. bought a new stake in shares of vTv Therapeutics in the 4th quarter valued at $221,000. Finally, 683 Capital Management LLC acquired a new position in vTv Therapeutics in the 4th quarter worth $731,000. Institutional investors own 17.51% of the company's stock.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company's lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.